Jämför metoder

	CAM Assay	Hemolysanalys
Ämnesområde	Biomaterial	Biomaterial
Familj	Process / pipeline	Process / pipeline
Ursprungsår	1974	1950
Upphovsperson	Judah Folkman	Clinical hematology traditions
Typ	Developmental biology assay	Hemolytic compatibility assay
Ursprungskälla	Folkman, J. (1974). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285(21), 1182-1186.	ASTM F756-17 (2017). Standard Practice for Assessment of Hemolytic Properties of Materials. ASTM International.
Alias	chick embryo chorioallantoic membrane, angiogenesis assay, CAM angiogenesis model	RBC lysis assay, hemolytic compatibility test, hemolytic potential test
Närliggande	4	4
Sammanfattning	The chorioallantoic membrane (CAM) assay is a well-established in vivo model for studying angiogenesis (new blood vessel formation) and evaluating the pro- or anti-angiogenic properties of biomaterials, drugs, and bioactive molecules. Developed by Judah Folkman in the 1970s, the assay uses the highly vascularized CAM of developing chick embryos as a platform for implanting test materials and observing vascular response. The CAM provides a transparent, immunologically naive microenvironment with rapid and reproducible neovascularization, making it ideal for screening angiogenic potential and assessing biomaterial biocompatibility.	The hemolysis assay is a standard method for evaluating the blood compatibility of biomaterials by quantifying the extent to which a material or substance damages red blood cells (RBCs) and causes hemoglobin release. Codified in standards including ASTM F756 and ISO 10993-4, the hemolysis assay is essential for regulatory approval of blood-contacting devices such as stents, catheters, artificial heart valves, and hemodialysis membranes. The assay provides a simple, quantitative measure of hemolytic potential that correlates with clinical safety.